Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Hospitalized with coronavirus (SARS-CoV-2) infection, confirmed by polymerase chain reaction (PCR) test or other commercial or public health assay in any specimen, as documented by either of the following:
Requires supplemental oxygen at the time of study entry and at randomization.
Have indicators of risk of progression: at least 1 inflammatory markers >upper limit of normal (ULN) (C reactive protein [CRP], D dimer, lactate dehydrogenase [LDH], ferritin) with at least 1 instance of elevation >ULN within 2 days before study entry.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
1,525 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal